Monday to Friday: 8 AM – 5 PM
(904) 893-3265
66%
MEDICATION NON-RESPONSE
Of Adolescents (15+) with major depression do not respond adequately to first-line antidepressant medications
2024–2026
FDA extended clearance to multiple TMS systems for Adolescents (15+) aged 15–21 with treatment-resistant depression
66%
TMS RESPONSE RATE
Response rate in Adolescents (15+) with treatment-resistant depression receiving TMS (1,120-patient real-world study)
78%
Of Adolescents (15+) experienced clinically meaningful improvement following a full TMS course
36
Sessions over 4–7 weeks comprise a full adolescent depression treatment course
Major depressive disorder affects Adolescents (15+) at significant rates, and nearly two-thirds of teenagers with depression do not achieve remission with standard antidepressants. When medications fail or cause intolerable side effects—weight gain, emotional blunting, sleep disruption, or sexual dysfunction—families require alternative options.
In 2024, the FDA cleared NeuroStar TMS for Adolescents (15+) aged 15–21 with treatment-resistant depression. Other systems are under FDA review. These clearances were supported by real-world data from 1,120 Adolescents (15+) treated across 35 TMS centers, showing 66% response rates and 78% clinically meaningful improvement.
FitMind Therapeutics offers this non-invasive, medication-free treatment in Jacksonville, FL. Our team specializes in treatment-resistant conditions affecting Adolescents (15+), providing an evidence-based pathway when conventional approaches fall short.
Depression in Adolescents (15+) often presents differently than in adults. Irritability may dominate over low mood. Social withdrawal can be extreme. Academic performance frequently collapses. When anxiety coexists—which occurs in approximately half of depressed Adolescents (15+)—symptom severity increases and treatment response decreases.
Depressive Domain in Adolescents (15+)
Persistent sadness or irritability most days
Loss of interest in hobbies, sports, and friends
Fatigue and low energy despite adequate sleep
Sleep disturbance — insomnia or sleeping excessively
Appetite change — weight loss or gain
Feelings of worthlessness or excessive guilt
Difficulty concentrating on schoolwork
Anxiety Domain in Adolescents (15+)
Excessive worry about school, social situations, or the future
Physical restlessness — feeling keyed up or on edge
Muscle tension without clear physical cause
Sleep disrupted by racing thoughts
Difficulty concentrating due to worry
Avoidance of anxiety-triggering situations (school refusal)
Irritability — easily annoyed or agitated
When both symptom clusters persist for more than two weeks with functional impairment—falling grades, withdrawing from friends, refusing school—clinical evaluation for TMS therapy in Adolescents (15+) is indicated, particularly after medication failures.
Standard antidepressants alter serotonin or norepinephrine systemically throughout the entire body, causing weight gain, sexual dysfunction, fatigue, and emotional numbness. For Adolescents (15+) who have failed these medications, TMS works entirely differently.
This non-invasive treatment delivers focused magnetic pulses (MRI-strength) directly to the left dorsolateral prefrontal cortex (L-DLPFC) — a brain region governing mood regulation, executive function, and cognitive control. Neuroimaging consistently shows this region is underactive during depressive episodes in Adolescents (15+), similar to adults.
Target: Left Dorsolateral Prefrontal Cortex (L-DLPFC)
This location is FDA-cleared for adolescent treatment-resistant depression. Stimulation produces downstream effects on limbic structures controlling mood and fear, restoring normal neurotransmitter function without systemic distribution.
Mechanism Summary:
Targets left DLPFC — established FDA location for adolescent depression
Uses focused MRI-strength magnetic pulses
Restores normal activity in mood-regulating circuits
No drugs, no sedation, no systemic effects — safe for developing brains
A full adolescent depression treatment course requires 36 sessions over 4–7 weeks. Treatment occurs Monday through Friday, allowing Adolescents (15+) to return to school immediately after each session.
Step 1:
Free Consultation
No-cost discussion of symptoms, prior medication trials, and TMS candidacy. Parental presence required.
Step 2:
Psychiatric Evaluation
Dr. Victoria Kozel, DNP or supervising psychiatrist Dr. Sarah Boaz assesses depression and anxiety history, prior medication trials (medications, doses, durations), and treatment goals. Both parental consent and adolescent assent are obtained.
Step 3:
Brain Mapping
Individual motor threshold determined. Left DLPFC mapped for precise targeting. Initial session: approximately 1.5 hours.
Step 4:
Daily Session
Adolescent reclines while magnetic coil delivers focused pulses. Approximately 18–30 minutes. Awake and alert throughout. May watch a movie, listen to music, or talk with staff.
Step 5 :
Immediate Return to Normal Life
No required downtime. Return to school, sports, or all regular activities immediately. Sessions Monday–Friday, 9:00 AM – 5:00 PM.
Feature
FDA Clearance for Adolescents (15+)
Invasiveness
Systemic Side Effects
Works When Medications Fail
Treatment Duration
Recovery Time
Insurance Coverage
TMS (Adolescent Ages 15–21)
✓ 2024–2026 (multiple systems)
✓ Non-invasive — no anesthesia
✓ None — mild scalp discomfort possible
✓ Yes
36 sessions over 4–7 weeks
✓ None — return to school same day
✓ Most major plans + TRICARE
SSRIs
✓ First-line
Systemic (oral)
Weight gain, sexual dysfunction, nausea, fatigue
No
Ongoing (months to years)
Variable
Routinely covered
CBT
✓ First-line
Non-invasive
None
Yes, but difficult if severe
12–20 sessions
None
Routinely covered
ECT
Off-label only
Invasive — anesthesia required
Memory loss, cognitive confusion
Yes
6–12 sessions
Extended recovery room
Specific indications
FDA cleared left DLPFC stimulation for adolescent treatment-resistant depression across multiple TMS systems between 2024 and 2026.
Finding
66%
12.1 points
78%
Comparable to adults
<1% serious adverse events
Data
Response rate in 1,120 Adolescents (15+) with treatment-resistant depression
Average PHQ-9 reduction (moderately severe to mild depression)
Clinically meaningful improvement documented on TrakStar platform
Adolescent response rates match or exceed adult TMS studies
Large systematic reviews confirm excellent safety profile when properly screened
No Symptom Provocation Required: Unlike some other protocols, adolescent depression TMS does not require symptom provocation. The standard left DLPFC protocol works directly on mood regulation circuits without triggering symptoms beforehand. The FDA clearances formalized what clinicians observed: treating the underactive left DLPFC improves depressive symptoms in Adolescents (15+).
“My 16-year-old tried three different antidepressants. Each caused different side effects — weight gain, emotional numbness, insomnia. Nothing helped the depression. TMS was different. Within four weeks, she was laughing again. She drove herself to every session and never missed a day of school.”
— Parent of 16-year-old female, treatment-resistant depression
“I was sure nothing would work. I’d been told my depression was ‘just hormones’ since I was 14. TMS didn’t feel like anything special at first. Then around week three, I realized I wasn’t dreading school every morning. By week six, I felt normal for the first time since middle school.”
— Jacob, age 17
(multiple medication failures)
“No weight gain. No sexual side effects like the SSRIs caused. No one at school knew I was getting treatment. I scheduled sessions during lunch, walked to the clinic, and went back to class. It worked when absolutely nothing else did.”
— Maya, age 16 (treatment-resistant depression with comorbid anxiety)
Transcranial magnetic stimulation is a non-invasive treatment that uses focused magnetic pulses to activate underactive brain regions involved in mood regulation. For Adolescents (15+) aged 15–21 with treatment-resistant depression, TMS is FDA-cleared and covered by most insurance plans.
Yes. Multiple TMS systems received FDA clearance for Adolescents (15+) aged 15–21 with treatment-resistant depression: NeuroStar (March 2024), BrainsWay Deep TMS (November 2025), Nexstim NBS 6 (March 2026), and Magstim Horizon/Inspire (2024–2025).
Yes. A real-world study of 1,120 Adolescents (15+) showed a 66% response rate (≥50% symptom improvement) and an average 12.1-point drop on the PHQ-9 scale. The NeuroStar TrakStar platform documented 78% clinically meaningful improvement.
Left dorsolateral prefrontal cortex (L-DLPFC) — involved in mood regulation, executive function, and cognitive control. Stimulation normalizes circuits responsible for depressive symptoms.
Many Adolescents (15+) and families notice improvement within 2–4 weeks. Full benefit typically emerges after completing all 36 sessions over 4–7 weeks.
Minimal. Mild scalp discomfort or transient headache during the first week. Unlike antidepressants: no weight gain, sexual dysfunction, nausea, dry mouth, or emotional blunting. Large systematic reviews confirm no serious adverse events when proper screening is performed.
Yes. TMS has been studied in Adolescents (15+) for over a decade and is well-tolerated. The FDA based its clearances on safety data from thousands of adolescent treatments. No anesthesia, no systemic side effects, and patients drive themselves or return to school immediately.
Most major insurers including Aetna, BCBS, Cigna, Humana, UnitedHealthcare, and TRICARE cover TMS for Adolescents (15+) when medication failures are documented. FitMind Therapeutics handles prior authorizations.
For Adolescents (15+) under 15, TMS is not FDA-cleared and is generally considered experimental. Some research protocols accept younger teens, but standard clinical treatment follows FDA clearance guidelines (ages 15+).
Medications circulate systemically causing weight gain, sexual dysfunction, fatigue, and emotional blunting. TMS targets brain circuits directly. Adolescent depression also shows poorer medication response, and SSRIs carry an FDA black box warning for suicidality in Adolescents (15+). TMS has no such warning.
Your adolescent does not have to continue living with depression that hasn’t responded to medications. TMS offers a proven, medication-free pathway — with most insurance plans covering treatment for qualified Adolescents (15+) aged 15–21.
Hours:
Office visits: Monday–Friday, 9:00 AM – 5:00 PM
TMS treatments: Monday–Friday, 9:00 AM – 5:00 PM
Saturday–Sunday: Closed
Languages: English, Russian, Ukrainian
Depression can make it difficult to enjoy the things you love in life, but there is hope for a better future. If your depression symptoms have not responded to your attempts at treatment, NeuroStar Advanced TMS Therapy in Jacksonville may be a good fit for you.
Our providers at FitMind Therapeutics are here to help. Schedule a consultation with our team today to determine whether TMS is the next step in your treatment plan.
Our HIPAA-compliant E-Fax number for referrals is (904) 659-8380.
Please include the following minimal patient information: first/last name, DOB, address, contact number/email, diagnosis, insurance and policy number, and name of referring provider.
TMS therapy is typically covered by most major insurance plans for the treatment of Major Depressive Disorder (MDD). If you're unsure whether your insurance covers your treatment, please contact us, and we'll be happy to verify your benefits on your behalf. For conditions that are not covered by insurance, we'll work with you to discuss alternative treatment and payment options.
